BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:HRS-4357 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of HRS-4357\, from ClinicalTrials.gov estima
 tes.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07311694-11070@assetmemo.bio
DTSTAMP:20261121T005708Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:HRS-4357: Phase 3 readout est. (NCT07311694)
DESCRIPTION:HRS-4357\, phase 3\, Metastatic Castration-Resistant Prostate C
 ancer.\nStudy: A Phase III Study Comparing HRS-4357 With Novel Androgen Re
 ceptor Pathway Inhibitors in Patients With Progressive\, PSMA-Positive Met
 astatic Castration-Resistant Prostate Cancer\nEstimated primary completion
 : December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/hrs-
 4357#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07311694
URL:https://assetmemo.bio/drug/hrs-4357#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
